Latest news for Bruker (NASDAQ:BRKR) Stock

Bruker

Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, pharmaceutical, and biotechnology industries. It operates in four operating segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from Asia Pacific.

stock-1863880

News

BRKR

Bruker shares are trading lower by 6.6% during Thursday&#39;s session. The company announced a public offering of 6 million shares of its common stock.

Why Bruker (BRKR) Shares Are Falling During Thursday&#39;s Session

Worst Performing

BBVA

DASH

GEHC

MSTR

SBUX

SMCI

STLA

SWKS

15 large-cap stocks had a rough week, with CVS, Starbucks, and DoorDash all taking major hits. Analysts have lowered price targets on many.

Last Week&#39;s Worst-Performing Stocks: Are These 15 Large-Cap Stocks In Your Portfolio? (April 28-May 4, 2024)

Red,Stock,Market,Price,Showing,Trader,Phobia,Of,Crisis,War

Movers

ANET

ASML

COIN

JBHT

TSLA

Last week&#39;s worst performers included Arm Holdings, Coinbase Global, Live Nation Entertainment and J.B. Hunt Transport Services.

Last Week&#39;s Worst-Performing Stocks: Are These 11 Large-Cap Stocks In Your Portfolio? (April 14-20, 2024)

Bruker Corp

Wells Fargo analyst Brandon Couillard initiates coverage on Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) with a Overweight rating and announces Price Target of $78.

Price Target

Initiation

Analyst Ratings

Wells Fargo Initiates Coverage On Bruker with Overweight Rating, Announces Price Target of $78

Asia's First 1.2 GHz NMR System Installed At Korea Basic Science Institute, Enhancing Molecular And Disease Research Capabilities

TD Cowen analyst Max Masucci maintains Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) with a Hold and lowers the price target from $74 to $72.

TD Cowen Maintains Hold on Bruker, Lowers Price Target to $72

The minority investment aims to accelerate the growth and further expansion of NovAliX, particularly within Europe and the United States.&nbsp;

Health Care

General

Bruker Announced A Minority Investment In NovAliX, A Preclinical Contract Research Organization Specializing In Drug Discovery Services, Financial Details Of The Investment Were Not Disclosed

Guidance

Bruker Sees FY24 Adj. EPS $2.59-$2.64 vs $2.64 Est., Revenues $3.38B-$3.44B vs $3.4B Est.

Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) reported quarterly earnings of $0.52 per share which met the analyst consensus estimate. The company reported quarterly sales of $800.700 million which beat the analyst consensus estimate of $796.541 million by 0.52 percent. This is a 17.42 percent increase over sales of $681.900 million the same period last year.

Earnings

Earnings Beats

Bruker Q2 2024 Adj. EPS $0.52, Inline, Sales $800.700M Beat $796.541M Estimate

Bruker Posted Bond In Order To Suspend Injunction That Had Been Impacting Sales Of CosMx Spatial Molecular Imager Products By Its NanoString Business In Germany

Citigroup analyst Patrick Donnelly maintains Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) with a Buy and lowers the price target from $95 to $80.

Citigroup Maintains Buy on Bruker, Lowers Price Target to $80

Goldman Sachs analyst Matthew Sykes maintains Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) with a Sell and lowers the price target from $72 to $60.

Goldman Sachs Maintains Sell on Bruker, Lowers Price Target to $60

Based on cellular biophysical markers attained using Bruker&#39;s advanced atomic force microscopy, Cellens is developing its platform for detecting bladder cancer using voided urine samples from cancer patients. The technology has shown outstanding sensitivity and specificity in pilot clinical studies.&nbsp;

Contracts

Cellens Is Collaborating With Bruker BioAFM, A Business Unit Of Bruker, To Develop The World's First Clinical Diagnostic Tests That Leverage Multi-parametric, Single-cell Biophysical Markers And Machine Learning

At the 72nd&nbsp;ASMS meeting,&nbsp;<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.bruker.com&amp;esheet=54025944&amp;newsitemid=20240603327426&amp;lan=en-US&amp;anchor=Bruker+Corporation&amp;index=1&amp;md5=a41daa44ad725e00e7727bb1f19c2f3e">Bruker Corporation</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) announced the launch of a novel, high-performance MALDI-TOF/TOF system, the&nbsp;neofleX Imaging Profiler&nbsp;for mass spectrometry-based tissue imaging. It enables facile OME-TIFF file output via the new&nbsp;SCiLS Scope&nbsp;software. The transformative neofleX MALDI-TOF/TOF MSI system now conveniently fits on a bench-top.
&nbsp;
&nbsp;
At the 72nd&nbsp;ASMS meeting,&nbsp;<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.bruker.com&amp;esheet=54025943&amp;newsitemid=20240603348539&amp;lan=en-US&amp;anchor=Bruker+Corporation&amp;index=1&amp;md5=2ceaf04d6f4b7914d0d2992ddf373d95">Bruker Corporation</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) launches the new top-of-the-line&nbsp;timsTOF Ultra 2&nbsp;system with significantly further enhanced sensitivity for deep profiling of small cells, subcellular organelles, as well as increased sample loading flexibility. Together with new&nbsp;Spectronaut 19software and the novel PreOmics&nbsp;ENRICHplus&nbsp;kit, Bruker is setting new 4D-Proteomics standards from highest sensitivity to large-scale, deep plasma proteomics. Bruker is also introducing&nbsp;OmniScape&nbsp;software for top-down sequence confirmation and&nbsp;de novo&nbsp;sequencing for intact, undigested proteoforms, dissociated in the mass spectrometer.

Bruker Launches NeofleX MALDI-TOF System for Spatial Biology Mass Spec Imaging (MSI) Applications, TimsTOF Ultra 2 to Enable New Research Paradigms in Single-Cell and Subcellular Proteomics

Bruker Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) shares are trading lower by 6.6% to $67.80 during Thursday&#8217;s session after the company announced a public offering of 6 million shares of its <a href="https://www.benzinga.com/pressreleases/24/05/b39076707/bruker-announces-pricing-of-public-offering-of-common-stock">common stock</a>.
The offering comes with an option for underwriters to purchase an additional 900,000 shares within 30 days. The offering is set to close around May 31, pending customary conditions. The proceeds will be used to reduce debt from recent strategic acquisitions, including repaying part of its revolving credit agreement. 
BofA Securities and J.P. Morgan are managing the offering, and the shares will be available on the Nasdaq Global Select Market and other venues at prevailing or negotiated prices.
See Also: <a href="https://www.benzinga.com/markets/equities/24/05/39085465/us-q1-economic-growth-downwardly-revised-to-1-3-consumer-spending-falters">US Q1 Economic Growth Downwardly Revised To 1.3%: Consumer Spending Falters</a>
<h2 class="wp-block-heading">Should I Sell My BRKR Stock?</h2>
When deciding to hold on to or sell a stock, investors should consider their time horizon, unrealized gains and total return.
Shares of Bruker have decreased by 5.73% in the past year. An investor who bought shares of Bruker at the beginning of the year would take a loss of $5.42 per share if they sold it today. The stock has fallen 15.38% over the past month, meaning an investor who bought shares on Apr. 1 would see a capital loss of $24.03.
Bruker shares have an all-time high of $94.27, representing 40.96% upside from current levels.
Investors may also consider market dynamics. The Relative Strength Index can be used to indicate whether a stock is overbought or oversold. Bruker stock currently has an RSI of 26.13, indicating oversold conditions.
For access to advanced charting and analysis tools and stock data, check out <a href="https://pro.benzinga.com/">Benzinga PRO. Try it for free.</a>
BRKR has a 52-week high of $94.86 and a 52-week low of $53.79.

Why Bruker (BRKR) Shares Are Falling During Thursday's Session

WIIM

Bruker shares are trading lower after the company announced a public offering of 6 million shares of its common stock.

Bruker intends to use the net proceeds from the offering to reduce indebtedness following its recent strategic acquisitions, including to repay a portion of its outstanding borrowings under the amended and restated revolving credit agreement dated as of January 18, 2024.

Reported Earlier, Bruker Prices Public Offering Of 6M Shares Of Common Stock

Bruker shares are trading lower after the company announced an underwritten registered public offering of 6 million shares of its common stock.

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.bruker.com&amp;esheet=54022322&amp;newsitemid=20240529283091&amp;lan=en-US&amp;anchor=Bruker+Corporation&amp;index=1&amp;md5=ab98aa193ce98152d1081babd0957b3e">Bruker Corporation</a> ("Bruker" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) today announced the launch of an underwritten registered public offering of 6,000,000 shares of its common stock. In addition, Bruker expects to grant the underwriters a 30-day option to purchase up to an additional 900,000 shares of its common stock. The offering is subject to market and other customary closing conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Bruker intends to use the net proceeds from this offering to reduce indebtedness following its recent strategic acquisitions, including to repay a portion of its outstanding borrowings under the amended and restated revolving credit agreement dated as of January 18, 2024. BofA Securities and J.P. Morgan are acting as joint underwriters and book-running managers for the offering.

Offerings

Bruker Announces Public Offering Of 6M Shares Of Common Stock

Bruker Files To Sell 6M Common Shares

Throughout the last three months, 4 analysts have evaluated Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>), offering a diverse set of opinions from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Bruker, presenting an average target of $85.75, a high estimate of $102.00, and a low estimate of $74.00. This upward trend is apparent, with the current average reflecting a 2.08% increase from the previous average price target of $84.00.
<img src="https://www.benzinga.com/files/images/story/2024/1716213638_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A clear picture of Bruker's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daniel Arias</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Hold</td>
<td>$77.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$90.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Matthew Sykes</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Sell</td>
<td>$74.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>John Sourbeer</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$102.00</td>
<td>$94.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Bruker. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Bruker compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Bruker's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Bruker's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BRKR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Bruker analyst ratings.</a>
<h2>Get to Know Bruker Better</h2>
Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, pharmaceutical, and biotechnology industries. It operates in four operating segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from Asia Pacific.
<h3>Bruker: Delving into Financials</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Bruker's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately 5.31%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Bruker's net margin excels beyond industry benchmarks, reaching 7.05%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Bruker's ROE stands out, surpassing industry averages. With an impressive ROE of 3.65%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Bruker's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.16%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a high debt-to-equity ratio of 1.03, Bruker faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>Analyst Ratings: Simplified</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Peeling Back The Layers: Exploring Bruker Through Analyst Insights

Stifel analyst Daniel Arias maintains Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) with a Hold and lowers the price target from $81 to $77.

Stifel Maintains Hold on Bruker, Lowers Price Target to $77

B of A Securities analyst Derik De Bruin maintains Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) with a Buy and lowers the price target from $95 to $90.

B of A Securities Maintains Buy on Bruker, Lowers Price Target to $90

Agilent Technologies

AbCellera Biologics

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solns

Charles River Laboratories International, Inc. Common Stock

Charles River

Danaher

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Bruker

News

Latest news for Bruker (NASDAQ:BRKR) Stock

People Also Watch